MedTrace Logo

Stroke in Young Fabry Patients (sifap2): Characterization of the Stroke Rehabilitation

NCT00413595 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2021-04-12

No results posted yet for this study

Summary

New studies indicate that in about 1 - 2 percent of the younger stroke patients the cause could have been an undiagnosed genetic disease, the so called Fabry disease. In this case certain fat molecules are not digested and broken down by the body - but remain in the cells. These fat molecules build up to dangerous levels, which start to damage the body, because they accumulate e.g. in the walls of the blood vessels. This accumulation in the blood vessels of the whole body may cause life-threatening malfunctions in the brain, inducing a stroke.

The purpose of this study is to investigate the stroke rehabilitation of Fabry patients during different therapeutic standard approaches for stroke and for Fabry disease (if any). During this study, stroke patients with Fabry disease will be monitored in greater detail to determine whether the differences in treatment are significant for patient recovery and on what they depend.

Conditions

Interventions

OTHER

No intervention

Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.

Sponsors & Collaborators

  • Shire Human Genetic Therapies, Inc.

    collaborator INDUSTRY

  • CENTOGENE GmbH Rostock

    lead INDUSTRY

Principal Investigators

  • Arndt Rolfs, Prof., MD · University of Rostock, Albrecht-Kossel-Institute for Neuroregeneration

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-07-31
Primary Completion
2019-12-01
Completion
2019-12-01

Countries

  • Austria
  • Croatia
  • France
  • Georgia
  • Germany
  • Poland
  • Portugal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00413595 on ClinicalTrials.gov